Radiopharmaceutical company Cyclopharm (ASX:CYC) has announced the appointment of Jason Smith as its chief financial officer.
Mr Smith has held several senior finance roles at Cochlear over the past 15 years. For the last seven years, he has been the director of financial planning and analysis for Asia Pacific.
Cyclopharm managing director and CEO James McBrayer said, "We are thrilled to welcome Jason to Cyclopharm as our new Chief Financial Officer. His extensive experience in senior finance roles, particularly his leadership in financial planning and analysis in the Asia Pacific region, will be invaluable to our company.
"The recent United States Food and Drug Administration approval for Technegas marks a pivotal moment for Cyclopharm, opening doors to substantial growth. Jason’s proven track record and strategic insights within the healthcare industry aligns very well with our goals. We are confident that his contributions will further enhance our financial capabilities and drive the company's success. We look forward to a prosperous future with Jason on board."